The Future of HER2+ Breast Cancer Treatment

In this episode of Emerging Experts, Paolo Tarantino, MD, discusses the latest developments in breast cancer research and treatment.

HER2DX has shown a strong association between ERBB2 mRNA and survival in patients with HER2-positive breast cancer.

In season 4, episode 2 of Targeted Talks, Sara A. Hurvitz, MD, discusses key advances in the HER2-positive breast cancer space and interesting ongoing research, namely trastuzumab deruxtecan.

During a Case-Based Roundtable® event, Ian Krop, MD, PhD, and event participants discussed how different types of metastases and treatment toxicity would affect therapy given to patients with triple-positive breast cancer in the second article of a 2-part series.

Mayra Shanley, PhD, discussed background and future directions for evaluating IL-21 natural killer cells for the treatment of glioblastoma.